Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

Yi Li, Yannan Zhao, Chengcheng Gong, Yizhao Xie, Xichun Hu, Jian Zhang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Biyun Wang, Yi Li, Yannan Zhao, Chengcheng Gong, Yizhao Xie, Xichun Hu, Jian Zhang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Biyun Wang

Abstract

Our study aimed to compare the efficacy and safety of nab-paclitaxel plus cisplatin (AP) with nab-paclitaxel plus gemcitabine (AG) in patients with metastatic breast cancer (MBC). We collected data from two single-arm, phase II MBC studies. In NCT01149798, seventy-three MBC patients received 125 mg/m2 nab-paclitaxel on days 1, 8 and 15 followed by 75 mg/m2 cisplatin on day 1 of a 28-day cycle. In NCT01550848, eighty-four MBC patients received 125 mg/m2 nab-paclitaxel and 800 mg/m2 gemcitabine on days 1, 8, and 15 of a 28-day cycle. The endpoints were the overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety profiles of these regimens. Among the 157 patients included, the ORR were 67.1% and 52.4% for the AP and AG arms, respectively (odds ratio [OR] = 0.246; hazard ratio [HR] = 1.485; 95% confidence interval [CI], 0.762-2.985). After median follow-up periods of 26.3 and 23.3 months in the AP and AG arms, the median PFS were 9.8 months (95%CI, 8.1-11.6) and 8.1 months (95%CI, 6.8-9.4), respectively, while the median OS were 26.9 months (95%CI, 22.4-31.4) and 25.5 months (95%CI, 19.3-31.4), respectively. Neither PFS nor OS adjusted for the number of metastases, occurrence of liver metastasis and chemotherapeutic lines differed significantly between the two arms (PFS:HR = 0.769; 95%CI, 0.541-1.092; p = 0.142; OS:HR = 0.686; 95%CI, 0.426-1.104; p = 0.120). However, PFS was significantly better with AP than with AG in metastatic triple-negative breast cancer (mTNBC) patients (HR = 0.308; 95%CI, 0.129-0.732; p = 0.008). Adverse events were more common with AP than with AG, except for edema and myalgia. Both regimens showed substantial efficacy and were tolerated well in MBC patients. mTNBC who received AP rather than AG showed longer PFS. However, adverse events were more common with AP. Thus, AP may be worth recommending to mTNBC, while AG may be a better alternative for MBC patients with other subtypes.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Forest plot of progression-free survival in AP and AG arms. Abbreviations: AP, nab-paclitaxel plus cisplatin; AG, nab-paclitaxel plus gemcitabine; HR, hazard ratio; CI, confidence interval; HER-2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer.
Figure 2
Figure 2
Kaplan–Meier curves for progression-free survival in triple-negative subgroup. Abbreviations: AP, nab-paclitaxel plus cisplatin; AG, nab-paclitaxel plus gemcitabine; HR, hazard ratio; CI, confidence interval.
Figure 3
Figure 3
Kaplan–Meier curves for overall survival in triple-negative subgroup. Abbreviations: AP, nab-paclitaxel plus cisplatin; AG, nab-paclitaxel plus gemcitabine; HR, hazard ratio; CI, confidence interval.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332.
    1. Ibrahim NK, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038–1044.
    1. Gradishar WJ, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803. doi: 10.1200/JCO.2005.04.937.
    1. Conlin AK, et al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010;10:281–287. doi: 10.3816/CBC.2010.n.036.
    1. Sun S, et al. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomedicine. 2014;9:1443–1452.
    1. Hu XC, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16:436–446. doi: 10.1016/S1470-2045(15)70064-1.
    1. Roy V, et al. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531) Ann Oncol. 2009;20:449–453. doi: 10.1093/annonc/mdn661.
    1. Albain KS, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26:3950–3957. doi: 10.1200/JCO.2007.11.9362.
    1. Yardley DA, et al. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2015;16:575. doi: 10.1186/s13063-015-1101-7.
    1. Yardley, D. et al. Nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. Cancer Res. 77 (2017).
    1. Gluz, O. et al. Comparison of Neoadjuvant Nab-Paclitaxel + Carboplatin vs Nab-Paclitaxel + Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. J Natl Cancer Inst (2017).
    1. Isakoff SJ, et al. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015;33:1902–1909. doi: 10.1200/JCO.2014.57.6660.
    1. Tutt, A. et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 75 (2015).
    1. Fan Y, et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol. 2013;24:1219–1225. doi: 10.1093/annonc/mds603.
    1. Vassilomanolakis M, et al. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol. 2000;11:1155–1160. doi: 10.1023/A:1008377724931.
    1. Vassilomanolakis M, et al. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cancer Invest. 2003;21:497–504. doi: 10.1081/CNV-120022358.
    1. Zhang J, et al. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol Ther. 2015;16:225–232. doi: 10.4161/15384047.2014.986973.
    1. Li Q, et al. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. Cancer Biol Ther. 2015;16:1746–1753. doi: 10.1080/15384047.2015.1095400.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir